Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.31 USD | -1.69% | -4.45% | -47.91% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Evolution of the average Target Price on ACADIA Pharmaceuticals Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering ACADIA Pharmaceuticals Inc.
JPMorgan Chase | |
UBS | |
Morgan Stanley | |
Deutsche Bank Securities | |
Cantor Fitzgerald | |
Baird | |
Needham & Co. | |
Oppenheimer | |
Canaccord Genuity | |
JMP Securities | |
RBC Capital Markets | |
Mizuho Securities | |
Stifel Nicolaus | |
Citigroup | |
HC Wainwright | |
BofA Securities | |
Guggenheim | |
Goldman Sachs | |
Loop Capital | |
SVB Securities LLC | |
Cowen | |
Jefferies & Co. | |
Berenberg Bank | |
SMBC Nikko | |
SVB Leerink | |
Raymond James |
EPS Revisions
- Stock Market
- Equities
- ACAD Stock
- Consensus ACADIA Pharmaceuticals Inc.